140 related articles for article (PubMed ID: 16034524)
21. Active immunotherapy of metastatic melanoma with allogeneic melanoma lysates and interferon alpha.
Vaishampayan U; Abrams J; Darrah D; Jones V; Mitchell MS
Clin Cancer Res; 2002 Dec; 8(12):3696-701. PubMed ID: 12473578
[TBL] [Abstract][Full Text] [Related]
22. Results of a phase II study of pemetrexed as first-line chemotherapy in patients with advanced or metastatic breast cancer.
Robert NJ; Conkling PR; O'Rourke MA; Kuefler PR; McIntyre KJ; Zhan F; Asmar L; Wang Y; Shonukan OO; O'Shaughnessy JA
Breast Cancer Res Treat; 2011 Feb; 126(1):101-8. PubMed ID: 21188632
[TBL] [Abstract][Full Text] [Related]
23. Eastern Cooperative Oncology Group phase II trial (E4296) of oral 5-fluorouracil and eniluracil as a 28-day regimen in metastatic colorectal cancer.
Marsh JC; Catalano P; Huang J; Graham DL; Cornfeld MJ; O'Dwyer PJ; Benson AB
Clin Colorectal Cancer; 2002 May; 2(1):43-50. PubMed ID: 12453335
[TBL] [Abstract][Full Text] [Related]
24. Pulse infusion interleukin-2 with famotidine and cyclophosphamide has activity in previously treated metastatic melanoma.
Quan W; Knupp C; Quan F; Walker P
Cancer Biother Radiopharm; 2010 Apr; 25(2):179-83. PubMed ID: 20423231
[TBL] [Abstract][Full Text] [Related]
25. A phase II study of epirubicin and thalidomide in unresectable or metastatic hepatocellular carcinoma.
Zhu AX; Fuchs CS; Clark JW; Muzikansky A; Taylor K; Sheehan S; Tam K; Yung E; Kulke MH; Ryan DP
Oncologist; 2005; 10(6):392-8. PubMed ID: 15967833
[TBL] [Abstract][Full Text] [Related]
26. A phase 2 trial of sequential temozolomide chemotherapy followed by high-dose interleukin 2 immunotherapy for metastatic melanoma.
Tarhini AA; Kirkwood JM; Gooding WE; Moschos S; Agarwala SS
Cancer; 2008 Oct; 113(7):1632-40. PubMed ID: 18720480
[TBL] [Abstract][Full Text] [Related]
27. A phase II study of cediranib, an oral VEGF inhibitor, in previously untreated patients with metastatic or recurrent malignant melanoma.
McWhirter E; Quirt I; Gajewski T; Pond G; Wang L; Hui J; Oza A
Invest New Drugs; 2016 Apr; 34(2):231-5. PubMed ID: 26841902
[TBL] [Abstract][Full Text] [Related]
28. Low-dose cyclophosphamide and continuous-infusion interleukin-2 with famotidine in previously treated metastatic melanoma or kidney cancer.
Quan WD; Quan FM; King LA; Walker PR
Cancer Biother Radiopharm; 2008 Feb; 23(1):108-13. PubMed ID: 18298334
[TBL] [Abstract][Full Text] [Related]
29. Prospective multicenter randomized phase III study of weekly versus standard docetaxel plus doxorubicin (D4) for first-line treatment of metastatic breast cancer.
Stemmler HJ; Harbeck N; Gröll de Rivera I; Vehling Kaiser U; Rauthe G; Abenhardt W; Artmann A; Sommer H; Meerpohl HG; Kiechle M; Heinemann V
Oncology; 2010; 79(3-4):204-10. PubMed ID: 21358208
[TBL] [Abstract][Full Text] [Related]
30. Paclitaxel and 5-fluorouracil in metastatic breast cancer: the US experience.
Paul DM; Garrett AM; Meshad M; DeVore RD; Porter LL; Johnson DH
Semin Oncol; 1996 Feb; 23(1 Suppl 1):48-52. PubMed ID: 8629038
[TBL] [Abstract][Full Text] [Related]
31. A phase I/II study of sequential, dose-escalated, high dose ifosfamide plus doxorubicin with peripheral blood stem cell support for the treatment of patients with advanced soft tissue sarcomas.
Bokemeyer C; Franzke A; Hartmann JT; Schöber C; Arseniev L; Metzner B; Link H; Kanz L; Schmoll HJ
Cancer; 1997 Oct; 80(7):1221-7. PubMed ID: 9317171
[TBL] [Abstract][Full Text] [Related]
32. Vinorelbine in combination with carboplatin followed by single-agent consolidation therapy for unresectable localized or metastatic non-small-cell lung carcinomas.
Alici S; Coskun U; Alkis N; Sevinc A; Dane F; Gumus M; Ozkan M; Kaya AO; Celenkoglu G; Buyukberber S; Altunbas M; Benekli M;
Asian Pac J Cancer Prev; 2009; 10(6):1051-5. PubMed ID: 20192582
[TBL] [Abstract][Full Text] [Related]
33. A phase II study of oxaliplatin, docetaxel, and GM-CSF in patients with previously treated advanced melanoma.
Locke F; Clark JI; Gajewski TF
Cancer Chemother Pharmacol; 2010 Feb; 65(3):509-14. PubMed ID: 19597729
[TBL] [Abstract][Full Text] [Related]
34. Epirubicin and paclitaxel with G-CSF support in first line metastatic breast cancer: a randomized phase II study of dose-dense and dose-escalated chemotherapy.
Lalisang RI; Erdkamp FL; Rodenburg CJ; Knibbeler-van Rossum CT; Nortier JW; van Bochove A; Slee PH; Voest EE; Wils JA; Wals J; Loosveld OJ; Smals AE; Blijham GH; Tjan-Heijnen VC; Schouten HC
Breast Cancer Res Treat; 2011 Jul; 128(2):437-45. PubMed ID: 21584666
[TBL] [Abstract][Full Text] [Related]
35. Phase I and pharmacologic study of sequential topotecan-carboplatin-etoposide in patients with extensive stage small cell lung cancer.
Miller AA; Al Omari A; Murry DJ; Case D
Lung Cancer; 2006 Dec; 54(3):379-85. PubMed ID: 17049403
[TBL] [Abstract][Full Text] [Related]
36. A phase II study of biochemotherapy for the treatment of metastatic malignant melanoma.
Gibbs P; Iannucci A; Becker M; Allen J; O'Driscoll M; McDowell K; Williams P; Rosse P; Murphy J; Gonzalez R
Melanoma Res; 2000 Apr; 10(2):171-9. PubMed ID: 10803718
[TBL] [Abstract][Full Text] [Related]
37. A phase II study of ispinesib (SB-715992) in patients with metastatic or recurrent malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group trial.
Lee CW; Bélanger K; Rao SC; Petrella TM; Tozer RG; Wood L; Savage KJ; Eisenhauer EA; Synold TW; Wainman N; Seymour L
Invest New Drugs; 2008 Jun; 26(3):249-55. PubMed ID: 17962907
[TBL] [Abstract][Full Text] [Related]
38. Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study.
Agarwala SS; Kirkwood JM; Gore M; Dreno B; Thatcher N; Czarnetski B; Atkins M; Buzaid A; Skarlos D; Rankin EM
J Clin Oncol; 2004 Jun; 22(11):2101-7. PubMed ID: 15169796
[TBL] [Abstract][Full Text] [Related]
39. Phase-II study of recombinant alpha 2-interferon in advanced malignant melanoma.
Coates A; Rallings M; Hersey P; Swanson C
J Interferon Res; 1986 Feb; 6(1):1-4. PubMed ID: 2871116
[TBL] [Abstract][Full Text] [Related]
40. Paclitaxel by 24- or 1-hour infusion n combination with carboplatin in advanced non-small cell lung cancer: the Fox Chase Cancer Center experience.
Langer CJ; Leighton JC; Comis RL; O'Dwyer PJ; McAleer CA; Bonjo CA; Engstrom PF; Litwin S; Johnson S; Ozols RF
Semin Oncol; 1995 Aug; 22(4 Suppl 9):18-29. PubMed ID: 7544025
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
